BC Innovations | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
BC Week In Review | Dec 24, 2001
Company News

Chiron other research news

Scientists reported in the Proceedings of the National Academy of Sciences evidence that the genes axin2 and hnkd could be used as biomarkers for activation of the Beta-catenin pathway, which is involved in tumorigenesis, in...
Items per page:
1 - 2 of 2